BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

Table 5

The associations between BMP-4 polymorphisms and PFS and OS of NSCLC patients undergoing chemotherapy.

BMP-4 polymorphisms	Median PFS, mo; (95% CI)	Log-rank 𝑃^†	Median OS, mo; (95% CI)	Log-rank 𝑃^†
−5826G > A
GG	8.4 (4.5–10.2)	0.659	17.5 (7.6–22.4)	0.364
GA	7.9 (5.0–9.1)		18.1 (7.7–20.8)
AA	8.2 (4.9–7.7)		17.1 (6.9–19.5)
6007C > T
TT	6.6 (5.5–8.2)	0.492	13.5 (5.6–18.8)	0.002
CT	7.0 (4.7–11.5)		14.7 (6.8–19.4)
CC	8.9 (5.4–12.1)		18.4 (11.8–19.5)
BMP-4 expression
Low	10.0 (8.1–17.5)	<0.001	18.6 (9.9–23.2)	<0.001
High	6.2 (4.9–10.7)		9.8 (5.1–13.2)

†Adjusted with age, sex, smoke status, histology, stage, and chemotherapy agents.